Waldencast (WALD) Projected to Post Quarterly Earnings on Tuesday

Waldencast (NASDAQ:WALD) is projected to release its earnings data after the market closes on Tuesday, March 18th. Analysts expect Waldencast to post earnings of ($0.07) per share and revenue of $70.43 million for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Waldencast Stock Up 3.5 %

Shares of Waldencast stock opened at $3.21 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.47 and a quick ratio of 0.78. The company’s fifty day simple moving average is $3.24 and its two-hundred day simple moving average is $3.47. Waldencast has a 12-month low of $2.41 and a 12-month high of $7.54.

Analysts Set New Price Targets

A number of brokerages have issued reports on WALD. DA Davidson boosted their price objective on shares of Waldencast from $7.25 to $7.50 and gave the company a “buy” rating in a research report on Wednesday, December 4th. Canaccord Genuity Group boosted their price objective on shares of Waldencast from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Friday, November 22nd. Telsey Advisory Group reaffirmed an “outperform” rating and issued a $6.00 target price on shares of Waldencast in a research report on Tuesday, March 11th. Finally, TD Cowen assumed coverage on shares of Waldencast in a research report on Monday, December 16th. They issued a “hold” rating and a $4.30 target price on the stock. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $5.76.

Waldencast Company Profile

Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians.